Clinical Observation on the Effect of Tongbi Heji plus Syndrome Differentiation Treatment for 90 Rheumatoid Arthritis Patients

GUO Feng-lian1; HAN Chao1; LIU Qing-ping2; et al.

doi:10.13288/j.11-2166/r.2008.10.013

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on the Effect of Tongbi Heji plus Syndrome Differentiation Treatment for 90 Rheumatoid Arthritis Patients

更新时间：2021-11-17

- Clinical Observation on the Effect of Tongbi Heji plus Syndrome Differentiation Treatment for 90 Rheumatoid Arthritis Patients
- Journal of Traditional Chinese Medicine Issue 10, Pages: 897-900(2008)
- 作者机构：
  
  1. 广州市中医医院中医中药研究所
  2. 广州中医药大学第一附属医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2008.10.013
  CLC： R259
- Published：2008
- 稿件说明：
移动端阅览
[1]郭凤莲,韩超,刘清平,刘丽娟.通痹合剂结合中医辨证治疗类风湿关节炎90例临床观察[J].中医杂志,2008(10):897-900.

GUO Feng-lian1, HAN Chao1, LIU Qing-ping2, et al. Clinical Observation on the Effect of Tongbi Heji plus Syndrome Differentiation Treatment for 90 Rheumatoid Arthritis Patients[J]. Journal of Traditional Chinese Medicine2008, (10): 897-900.
[1]郭凤莲,韩超,刘清平,刘丽娟.通痹合剂结合中医辨证治疗类风湿关节炎90例临床观察[J].中医杂志,2008(10):897-900. DOI： 10.13288/j.11-2166/r.2008.10.013.

GUO Feng-lian1, HAN Chao1, LIU Qing-ping2, et al. Clinical Observation on the Effect of Tongbi Heji plus Syndrome Differentiation Treatment for 90 Rheumatoid Arthritis Patients[J]. Journal of Traditional Chinese Medicine2008, (10): 897-900. DOI： 10.13288/j.11-2166/r.2008.10.013.

摘要

目的评价通痹合剂结合辨证治疗类风湿关节炎（RA）的临床疗效。方法将90例RA患者随机分为两组

中药组以通痹合剂结合辨证口服中药治疗

西药组口服尼美舒利、甲氨蝶呤、柳氮磺胺吡啶治疗。治疗3个月后

观察两组疗效及相关生化指标。结果两组均能改善RA患者症状、减轻关节肿胀指数、压痛指数

降低血沉（ESR）、C反应蛋白（CRP）（P<0.01）;并且中药组对RA患者症状的改善、患者及医生对病情的总体评价也优于西药组（P<0.05）。结论通痹合剂结合中医辨证治疗能有效治疗RA

未见明显不良反应。

Abstract

Objective To evaluate the therapeutic effect of Tongbi Heji（Mixture for arthralgia）plus syndrome differentiation treatment on rheumatoid arthritis（RA）.Methods The 90 cases were randomized into two groups.The Chinese medicine group was treated with Tongbi Heji plus herbal medicines for oral taking based on syndrome differentiation.The western medicine group was administered nimesulide

methotrexate and sulfasalazine.The effect of two groups and the changes in biochemical examination were observed for comparison after 3 months’ treatment.Results In both groups

the symptoms were relieved

the indices of joint swelling and tenderness reduced

and the erythrocyte sedimentation rate（ESR）and reactive protein C（CRP）lowered（P<0.01）.The improvement of pathological condition of RA patients in the Chinese medicine group and the overall evaluation of patients and doctors were all better than those of western medicine group.Conclusion Tongbi Heji plus syndrome differentiation treatment can treat RA effectively and improve the pathological condition of patients.The side effect is less.

关键词

Keywords

references

查看原文

Views

191

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Observation on Qingre Huoxue Decoction for 71 Patients with Rhe umatoid Arthritis

Correlation of Joint Function Degree and TCM Syndromes in Rheumatoid Arthritis

Clinical Study on Erteng Tongbi Mixture plus Zhengqing Fengtongning Sustained Released Tablet in the Treatment of Rheumatoid Arthritis:A Report of 30 Cases

Preliminary Construction of Questionnaire Based on Rheumatoid Arthritis Patients-Reported Outcomes

A Preliminary Discussion on the Method of Regulating Qi and Calming the Mind

Related Author

JIAO Juan1

TAN G Xiaopo1

CAO Wei1

WANG Yuming3

WANG Chengde2

FENG Xinghua1

JIANG Quan1

HE Wei1

Related Institution

Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 3

Beijing Shuntiande Hospital of Chinese Medicine

Beijing Traditional Chinese Medicine Hospital,Capital University of Medical Sciences

The Second TCM Hospital of Guangdong Province

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰